[Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
D000284:Administration, Oral; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D000077592:Maraviroc; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D019562:Viral Load
D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc